GW 4064 is a synthetic small molecule selective agonist of the orphan nuclear receptor FXR (EC50=15nM) developed by GlaxoSmithKline. Protects cells and organs against bile acid toxicity, and used to elucidate FXR's role in dyslipidemia, diabetes, obesity, and cancer. Has no activity against other nuclear receptors.